The Multiple Myeloma Channel on VJHemOnc is an independent medical education platform, supported with funding from BMS (Gold) and Legend Biotech (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
BSH 2022 | The impact of lenalidomide maintenance therapy on myeloma patients in the UK
Karthik Ramasamy, MBBS, MRCP, FRCPath, PhD, Oxford University Hospitals NHS Foundation Trust, Oxford, UK, discusses how maintenance therapy has improved outcomes for patients with multiple myeloma and the benefit this brings for patients in the UK. Dr Ramasamy briefly mentions data from the Myeloma XI study (NCT01554852), which has shown that lenalidomide maintenance improves progression-free survival (PFS) and overall survival (OS) in patients. Dr Ramasamy then discusses patients with high-risk disease who do not obtain durable remissions with lenalidomide maintenance, and the need to find combination treatments for these patients, which is currently being investigated in the RADAR trial (ISRCTN46841867). This interview took place at the 62nd Annual Scientific Meeting of the British Society for Haematology (BSH) 2022, in Manchester, UK.
